| Bioactivity | PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between PD-1 and PD-L1. PD-1/PD-L1-IN-43 can be used in anti-tumor studies[1]. |
| Invitro | PD-1/PD-L1-IN-43 (0 - 20 μM; 48 h) 可以激活免疫抑制的 Jurkat T 细胞，杀死细胞共培养系统中的 HepG2 细胞[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PD-1/PD-L1-IN-43 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | PD-1/PD-L1-IN-43 (20 和 40 mg/kg； 腹腔注射， 每天一次持续 2 周) 通过激活肿瘤免疫微环境有效抑制 C57BL/6J 雄性小鼠体内肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C27H25N3O4 |
| Molar Mass | 455.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xu C, et al. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction[J]. Bioorganic Chemistry, 2024: 107376. |